TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03946176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DVB cartridge
Description: On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVB cartridge
Description: On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
Study: NCT04022746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo multiparametric MRI/MRE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo multiparametric MRI/MRE
Study: NCT02315521

Intervention type: PROCEDURE
Intervention: Fetal Intervention for LUTO
Description: Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves.

Intervention type: PROCEDURE
Intervention: Fetal Intervention for LUTO
Description: Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves.

Intervention type: PROCEDURE
Intervention: Fetal Intervention for LUTO
Description: Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves.
Study: NCT04020744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: real-time fMRI based neurofeedback from the hippocampus
Description: During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real-time fMRI based neurofeedback from the hippocampus
Description: During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
Study: NCT02969018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Study: NCT01633645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
Study: NCT01473953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide-depot
Description: Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide-depot
Description: Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide-depot
Description: Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide-depot
Description: Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
Study: NCT00939718

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B12
Description: Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
Study: NCT03059628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: This PNF technique use information designed to correct normative misperceptions to reduce heavy drinking. Much of the alcohol consumption among college students stems from the fairly widespread perception that one's peers expect regular and sometimes extreme drinking participation (subjective drinking norms). The PNF approach is designed to counter this perception by giving students accurate figures on how much their peers actually drink (actual drinking norms). It also aims to improve students' understanding of alcohol use in general and the firmly established negative outcomes associated with short - and long-term patterns of excessive drinking.
Study: NCT04288544

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microalgae
Description: Open, monocentric intervention study in crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microalgae
Description: Open, monocentric intervention study in crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3-fatty acid capsule
Description: Open, monocentric intervention study in crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3-fatty acid capsule
Description: Open, monocentric intervention study in crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sea fish
Description: Open, monocentric intervention study in crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sea fish
Description: Open, monocentric intervention study in crossover design
Study: NCT02430129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicompartment knee arthroplasty
Description: Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona
Description: Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxford
Description: Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
Study: NCT02550769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRANSANAL TOTAL MESORECTAL EXCISION
Description: The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic-LAR
Description: Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
Study: NCT00925743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel (XRP6258)
Description: * administered by IV infusion~* in addition to cisplatin treatment
Study: NCT02772198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T cells
Description: Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
Study: NCT02162576

Intervention type: DEVICE
Group type: OTHER
Intervention: Propeller Health intervention
Description: The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
Study: NCT04441762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketorolac Tromethamine
Description: 30 mg ketorolac single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketorolac Tromethamine
Description: 30 mg ketorolac single dose
Study: NCT04144491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100ml of custard will be consumed 5 days per week, for 9 weeks.
Study: NCT01419821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 800IU (4gtt/d) once a day for 2 years once a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Vitamin D)
Description: 4gtt/d for the placebo for two years.
Study: NCT04357691

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional training
Description: Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional training
Description: Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional training
Description: Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AI-led training
Description: Participants will perform an AI-led training for 4 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AI-led training
Description: Participants will perform an AI-led training for 4 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AI-led training
Description: Participants will perform an AI-led training for 4 weeks
Study: NCT02555280

Intervention type: DEVICE
Group type: OTHER
Intervention: coflex® Interlaminar Technology
Description: Decompression plus coflex® Interlaminar Technology

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Decompression alone
Study: NCT00593580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate/cholecalciferol
Description: FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
Study: NCT01089361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline placebo
Description: The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
Study: NCT03504137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Study: NCT04935671

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chamomile tea n saffron
Description: 20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
Study: NCT03993093

Intervention type: OTHER
Intervention: CD4 cell count
Description: CD4 cell count from treatment naive HIV patients
Study: NCT04253509

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Tumor DNA Methylation Sequencing
Description: Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Tumor DNA Methylation Sequencing
Description: Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
Study: NCT02485678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Telephone Toxicity Management
Description: Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRO Sub-Study
Description: A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO Sub-Study
Description: A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
Study: NCT00278408

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT00278915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive intramuscular injection of fulvestrant as stated in arm description.
Study: NCT02780323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CELBESTA®
Description: 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CELEBREX®
Description: 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CELEBREX® placebo
Description: 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CELBESTA® placebo
Description: 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
Study: NCT04592263

Intervention type: OTHER
Intervention: EPD Questionnaire
Description: A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
Study: NCT04173793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection
Study: NCT03059628

Intervention type: OTHER
Group type: OTHER
Intervention: Brief Therapeutic Intervention
Description: BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.
Study: NCT04020744

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: real-time fMRI based neurofeedback from another brain area
Description: During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
Study: NCT03059628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Therapeutic Intervention
Description: BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation questionnaire
Description: The patient have to fill the same evaluation questionnaire at J0, M6 and M12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation questionnaire
Description: The patient have to fill the same evaluation questionnaire at J0, M6 and M12